The skeptics are right about most of the market.
The right question is what each clinic operationalizes.
In spring 2026, three things happened in close succession. CNN published "Peptides: what's real, what's risky and what's next." Eric Topol published "The Peptide Craze" on Ground Truths. And a stretched wellness industry kept doing exactly what those pieces were warning about — prescribing without baseline labs, sourcing without 503A oversight, titrating without follow-up, and selling without disclosing what the evidence supports.
The critics are largely correct. The market is full of practices that deserve the skepticism — some NP-led, some physician-led, some neither. The shorthand "physician vs. NP" is too coarse: there are excellent NP-staffed practices and there are physician-owned practices that are doing exactly what the critics describe. What matters is not the title on the door. It is what the practice operationalizes — structured labs, vetted compounding, defined endpoints, evidence tiers in writing, and an honest informed-consent process the patient can audit.
This page is the side-by-side. Each concern the skeptics raise — fairly — paired with exactly what Limitless does about it. No vague reassurance; the specific operational answer. If a competing clinic does the same things, that is good for patients. The differentiation is the operational rigor, in writing.
"Sourcing is opaque. Patients don't know where the peptide came from."
The CNN piece flags it directly: research-grade powder, gray-market imports, peptides "for research only" being injected into humans. The patient often has no way to find out.
503A-pharmacy sourcing, audited, on file.
Every Limitless peptide and compounded hormone is dispensed through a licensed 503A pharmacy. We audit our partners on USP 797/795 compliance, COA reporting, and beyond-use dating. We are on track for two qualified pharmacy partners on file by June 1, 2026 — operational redundancy so a single supply event cannot interrupt your care. Pharmacy name and COA available on request.
"They prescribe without baseline labs."
Topol's central frustration: TRT and peptides being initiated with no objective starting point, no follow-up labs, no way to know whether the intervention is working or whether the patient is drifting into harm (elevated hematocrit, lipid shifts, hepatic stress).
Baseline labs are mandatory.
Every Limitless patient gets a comprehensive baseline lab panel before a prescription is written — total and free testosterone, estradiol, SHBG, LH, FSH, prolactin, complete metabolic panel, complete blood count, lipid panel, hsCRP, fasting insulin, A1c, IGF-1, ferritin, thyroid, vitamin D. We review the results with the patient before prescribing. Labs at 90 days. Labs again at 6 months and annually. No exceptions.
"They prescribe based on vibes, not indications."
"Feel-better peptides" without a named clinical indication. Open-ended protocols that just keep going. No clearly defined endpoint where success or failure can be measured.
Indication-anchored, with defined endpoints.
Every Limitless prescription is tied to a named clinical indication in the chart: hypogonadism by Endocrine Society criteria, perimenopausal symptom burden, tendinopathy with stalled rehab, visceral adiposity for tesamorelin, etc. Tissue-repair & recovery peptide courses are defined as 4–8 week protocols with documented reassessment — not open-ended scripts. If the indication isn't there, the prescription isn't either.
"They claim things the literature doesn't support."
"Reverses aging." "Cures fatigue." "Adds a decade." The marketing oversteps what the trials show. Patients are misled about the magnitude and certainty of effect.
Evidence tiers in writing, before the prescription.
Our peptide evidence framework sorts every category on our menu into FDA-approved, supported-with-meta-analysis, or supported-by-mechanism-and-pilots. The patient sees the tier in plain language before signing consent. Tesamorelin and daily tadalafil are FDA-approved. Tissue-repair peptides are voluminous preclinical with thin human data. NAD+ is well-characterized biology with maturing endpoint trials. We say so out loud.
"The clinician on the prescription is not the clinician on the case."
In many regenerative-medicine practices the patient meets one clinician for the consult, a different one signs the prescription, and a third manages follow-up. Scope-of-practice questions get answered by org charts rather than by who actually understands the patient's labs over time.
The physician you book with is your physician.
Every Limitless protocol is written by Joshua Hare, DO — an osteopathic physician with a hospital-based, interventional clinical background, currently practicing at Interventional Pain Consultants in Dalton. There is no "supervising physician" relationship behind a curtain and no rotating prescriber. The physician you book with is the physician who reads your labs, signs your protocol, and reviews your follow-up. Single point of clinical responsibility from intake through annual maintenance.
"Once the protocol starts, no one is watching it."
Initiation without surveillance. No one checking hematocrit on TRT at 90 days. No one re-running estradiol after a dose change. No one watching the prostate or the lipid panel. Drift becomes harm.
Surveillance is the protocol.
The Limitless lab cadence is 0 → 90 days → 6 months → annual, with interim labs after any dose change. Hematocrit, estradiol, SHBG, lipids, LFTs, PSA (men 40+), thyroid, A1c. We titrate — we do not "set and forget." When a value moves, we have a chart-documented response: dose adjustment, donation referral for elevated hematocrit, hepatology workup for persistent transaminitis, etc.
"They prescribe a libido peptide, oral tissue-repair peptides, and 'NAD nasal sprays' because it sells."
The peptide market is increasingly cluttered with products whose pharmacokinetic or safety data does not support common use. The default menu of many practices is shaped by what is profitable, not what is supportable.
What we don't prescribe, in writing.
A libido peptide is not on our default menu — selected use only with documented indication, and only where lawful. Oral tissue-repair peptides are not on our menu — the route is not well-characterized. NAD+ patches and nasal sprays are not on our menu — the pharmacokinetic data does not support them. We publish what we don't prescribe and why, on this page and inside our research library.
"The regulatory picture is unstable — what happens after PCAC?"
The regulatory picture moved twice in 2026, and the July 23–24 PCAC meeting reshaped the durable shelf status again. Patients deserve to know that the legal picture six months from now may differ from the picture today.
Correction, 2026-08-19: an earlier version of this card said the April 23, 2026 action "restored" compounded peptides. That was wrong, and we have corrected it wherever it appeared. Adding these substances would create lawful access for the first time — it would not restore something that previously existed. We are logging the fix rather than quietly deleting it.
We have a written continuity plan.
See our legal-status briefing and the tissue-repair peptide PCAC summary. Two qualified 503A partners by June 1 (insulation against single-source supply tightening). A planned post-PCAC update by July 30 with operational implications for current patients. Indication-anchored prescribing means we are not exposed to "discontinued wellness peptide" risk.
"Nobody is counting the harms."
This is the sharpest criticism of the entire compounded-peptide space, and it came from health-policy scholars in Health Affairs in August 2026: section 503A largely exempts compounded preparations from FDA oversight — including adverse-event reporting requirements that apply to approved drugs. Expanding the bulks list expands patient exposure without expanding safety surveillance. Separately, when the Georgia Composite Medical Board began unannounced inspections of med spas and IV clinics this summer, one of the findings reported was operators failing to track adverse events at all.
We track adverse events as if we were required to.
We are not going to argue this criticism away, because it is correct. The federal surveillance gap is real, and no clinic can close it alone. What a single practice can do is refuse to benefit from it. Every Limitless patient is asked about tolerance and side effects at each check-in, and every reported event — including the minor and the ambiguous — is recorded in a structured internal register with the substance, lot and pharmacy, dose, timing, and outcome. Serious events are reported to the dispensing pharmacy and, where a marketed product is involved, to FDA MedWatch. We report to MedWatch voluntarily, because for compounded preparations the obligation does not attach. Lot and pharmacy are captured on every dispense so that if a signal appears, we can identify every affected patient the same day rather than reconstructing it from memory.
"The physician on the website doesn't own the clinic — or work there."
The dominant structure in this industry is a management company that owns the brand, the lease, the inventory and the revenue, with a professional entity holding the license. Georgia's corporate practice of medicine doctrine exists to prevent lay corporations from controlling medical judgment. The Georgia Board's May 7, 2026 position statement bars a physician from being financially dependent on the APRN they supervise and expressly names third-party medical-director matching services — an industry that exists because clinics need a signature more than they need a physician.
Physician-owned, not just physician-led.
"Physician-led" is a phrase anyone can print. Ownership is a fact you can verify. Limitless Performance Medicine is owned and operated by Joshua Hare, DO. There is no management services organization, no franchisor, no private-equity sponsor, no rented medical director, and no matching service. The physician who signs your protocol is the physician who owns the practice and carries the license it operates under — which means when medicine and margin disagree here, there is no second party to resolve it in favor of margin. If that structure ever changes, this page will say so before you hear it anywhere else.
What we guarantee in writing.
Physician signs every script.
Joshua Hare, DO — the physician you book with — is the physician who reads your labs and signs your protocol. No supervising-physician proxies.
503A-only sourcing.
Licensed compounding pharmacy on every prescription. COA available on request. Two-partner redundancy targeted by June 1, 2026.
Baseline + cadence labs.
Comprehensive baseline. Labs at 90 days, 6 months, and annually. Interim labs after any dose change. No prescriptions without labs.
Indication in the chart.
Every prescription tied to a named clinical indication. Defined courses for peptides. Documented reassessment.
Evidence tier before consent.
You see the literature behind the prescription — FDA-approved, meta-analysis, or mechanism-and-pilot — in writing, before you sign.
Honest "no."
If the indication isn't there, or the evidence doesn't support it, we say so. We publish what we don't prescribe.
Adverse events tracked and reported.
Structured internal register with substance, lot, pharmacy, dose and outcome. Serious events reported to the dispensing pharmacy and voluntarily to FDA MedWatch — an obligation §503A does not impose on compounded preparations.
Physician-owned.
Owned and operated by Joshua Hare, DO. No management company, no franchisor, no private-equity sponsor, no rented medical director, no matching service. If that changes, this page says so.
Read the literature behind every protocol — before you decide.
Every Limitless protocol has a paper trail. Our research library is public, primary-source-cited, and physician-authored. If you are skeptical, start there.
Open the Research LibraryWhen you are ready, book a consult — we will go through your goals, your history, and exactly what an indicated, lab-anchored Limitless protocol would look like for you.
Physician-led care in Dalton, Georgia.
Limitless Performance Medicine is a physician-led practice. Consultations are by appointment.